Outlook Therapeutics Inc

Research Outlook Therapeutics Inc (OTLK) on Bullrun: market cap USD 204.26M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerOTLK
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 204.26M
• Financial periodFY2025
• RevenueUSD 1.41M
• Net income-USD 62.42M
• Gross margin4.0%

Valuation Snapshot

latest market cap is USD 204.26M.

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc.

Frequently asked questions

What is Outlook Therapeutics Inc's market cap?

Outlook Therapeutics Inc's market capitalization is USD 204.26M.

What does Outlook Therapeutics Inc do?

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.